Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Operating Income Loss of -$62.28 million for the year ending 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -176.3% in Operating Income Loss from 2024 to 2025.
- This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 55.2%.
- Historical annual values: Fiscal year 2025: -$62.28 million | Fiscal year 2024: $81.67 million | Fiscal year 2023: -$5.27 million | Fiscal year 2022: $46.12 million | Fiscal year 2021: $86.03 million | Fiscal year 2020: $173.70 million | Fiscal year 2019: $148.57 million | Fiscal year 2018: $144.44 million | Fiscal year 2017: $99.54 million | Fiscal year 2016: $54.22 million | Fiscal year 2015: $20.84 million | Fiscal year 2014: -$5.28 million | Fiscal year 2013: -$61.92 million | Fiscal year 2012: -$42.17 million | Fiscal year 2011: -$37.75 million | Fiscal year 2010: -$40.12 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: